Global Rivaroxaban Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Rivaroxaban Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
Rivaroxaban report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Rivaroxaban market is projected to reach US$ 13970 million in 2034, increasing from US$ 7995 million in 2022, with the CAGR of 8.2% during the period of 2024 to 2034. Demand from Acute Coronary Syndrome (ACS) and Venous Thromboembolism (VTE) are the major drivers for the industry.
The major players in global Prom Dresses market include Bayer, Johnson and Johnson, etc. The top 2 players occupy nearly 100% of the market. Europe is the main market, and occupies nearly 100% of the global market. 10 mg is the main type, with a share over 30%. Venous Thromboembolism (VTE) is the main application, which holds a share about 85%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rivaroxaban market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Bayer
J&J
Segment by Type
2.5 mg
10 mg
15 mg
20 mg
Acute Coronary Syndrome (ACS)
Venous Thromboembolism (VTE)
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Rivaroxaban market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Rivaroxaban, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Rivaroxaban industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Rivaroxaban in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Rivaroxaban introduction, etc. Rivaroxaban Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Rivaroxaban market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Rivaroxaban report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Rivaroxaban market is projected to reach US$ 13970 million in 2034, increasing from US$ 7995 million in 2022, with the CAGR of 8.2% during the period of 2024 to 2034. Demand from Acute Coronary Syndrome (ACS) and Venous Thromboembolism (VTE) are the major drivers for the industry.
The major players in global Prom Dresses market include Bayer, Johnson and Johnson, etc. The top 2 players occupy nearly 100% of the market. Europe is the main market, and occupies nearly 100% of the global market. 10 mg is the main type, with a share over 30%. Venous Thromboembolism (VTE) is the main application, which holds a share about 85%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rivaroxaban market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bayer
J&J
Segment by Type
2.5 mg
10 mg
15 mg
20 mg
Segment by Application
Acute Coronary Syndrome (ACS)
Venous Thromboembolism (VTE)
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Rivaroxaban market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Rivaroxaban, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Rivaroxaban industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Rivaroxaban in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Rivaroxaban introduction, etc. Rivaroxaban Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Rivaroxaban market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices